| Dermatitis |
1 |
1 |
| COVID-19 |
0 |
0.8 |
| COVID-19 Vaccine |
0 |
0.75 |
| Atopic Dermatitis |
0 |
1 |
| Clinical Research |
0 |
0.37 |
| Oregon |
0 |
0.37 |
| Washington |
0 |
0.37 |
| Biologic Therapy |
0 |
0.32 |
| Tdap Vaccine |
0 |
0.4 |
| Vaccines |
0 |
0.24 |
| Meningococcal Disease |
0 |
0.21 |
| Cardiovascular disease |
0 |
0.19 |
| Diphtheria |
0 |
0.19 |
| Europe |
0 |
0.19 |
| Interleukin |
0 |
0.19 |
| Meningococcal Vaccine |
0 |
0.19 |
| Monoclonal Antibody |
0 |
0.19 |
| Pertussis |
0 |
0.19 |
| Severe Acute Respiratory Syndrome (SARS) |
0 |
0.19 |
| Steroids |
0 |
0.19 |
| Tetanus |
0 |
0.19 |
| Acute Respiratory Distress Syndrome |
0 |
0.05 |
| Asthma |
0 |
0.05 |
| Cardiovascular Risk Management |
0 |
0.05 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.05 |
| Obesity |
0 |
0.05 |
| Pediatric Respiratory Infections |
0 |
0.05 |